Dake Benjamin T. - 10 Aug 2022 Form 4 Insider Report for Aerovate Therapeutics, Inc. (JBIO)

Role
Officer Title: President, Chief Operating Officer and Secretary
Signature
/s/ George A. Eldridge, Attorney-in-Fact
Issuer symbol
JBIO
Transactions as of
10 Aug 2022
Net transactions value
-$314,122
Form type
4
Filing time
12 Aug 2022, 17:15:56 UTC
Previous filing
10 Aug 2022
Next filing
18 Aug 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVTE Common Stock Options Exercise $22,133 +12,720 $1.74* 12,720 10 Aug 2022 Direct F1
transaction AVTE Common Stock Sale $287,270 -11,940 -94% $24.06 780 10 Aug 2022 Direct F1, F2
transaction AVTE Common Stock Sale $19,096 -780 -100% $24.48 0 10 Aug 2022 Direct F1, F3
transaction AVTE Common Stock Options Exercise $2,344 +1,347 $1.74* 1,347 11 Aug 2022 Direct F1
transaction AVTE Common Stock Sale $30,292 -1,268 -94% $23.89 79 11 Aug 2022 Direct F1, F4
transaction AVTE Common Stock Sale $1,939 -79 -100% $24.55 0 11 Aug 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTE Stock Option (Right to Buy) Options Exercise $0 -12,720 -39% $0.000000 19,930 10 Aug 2022 Common Stock 12,720 $1.74 Direct F1, F5
transaction AVTE Stock Option (Right to Buy) Options Exercise $0 -1,347 -6.8% $0.000000 18,583 11 Aug 2022 Common Stock 1,347 $1.74 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.43 to $24.40, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.435 to $25.15, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.47 to $24.26, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F5 A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Remarks:

Officer Title: President, Chief Operating Officer and Secretary